NKTX Stock Analysis: Buy, Sell, or Hold?
NKTX - Nkarta, Inc. Common Stock
$2.32
0.13 (5.94%)
▲
5d:
+8.41%
30d:
-15.02%
90d:
+25.41%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Accumulation
NKTX is down 8.3% this week, but smart money is accumulating calls. Top strike: $2.5 2026-05-15 with 835 OI. Call ratio: 100% View Scanner →
Strength: 9.1/10
Get Alerted When NKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NKTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NKTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NKTX is currently trading at $2.32, which is considered fair relative to its 30-day fair value range of $2.13 to $2.57.
Technical Outlook: Technically, NKTX is in a strong uptrend. The price is approaching resistance at $2.31. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: NKTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.20 (+512.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NKTX is in a strong uptrend. The price is approaching resistance at $2.31. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: NKTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.20 (+512.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$2.13 -
$2.57
Company Quality Score
49/100
(HOLD)
Options IV Signal
63th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
58.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 63th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 512.1% below Wall St target ($14.20)
Fair Price Analysis
30-Day Fair Range
$2.13 -
$2.57
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.46
(19.9%)
Support & Resistance Levels
Support Level
$1.96
Resistance Level
$2.31
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.30
Wall Street Target
$14.20
(+512.1%)
Share & Embed Analysis
Last updated: April 03, 2026 1:02 AM ET
Data refreshes hourly during market hours. Next update: 2:02 AM
Data refreshes hourly during market hours. Next update: 2:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Nadir Mahmood
SELL
5649 shares
2026-01-15
Paul J Hastings
SELL
26046 shares
2026-01-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 65 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 61 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 50 HOLD |
